全球血漿蛋白治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計血漿蛋白療法市場將從 2025 年的 238.5 億美元成長到 2034 年的 430.1 億美元，2026 年至 2034 年的複合年成長率為 6.77%。

由於血漿衍生產品在免疫力缺乏、出血性疾病和神經系統疾病的治療中應用日益廣泛，全球血漿蛋白治療市場正在擴張。人們對罕見疾病的認知不斷提高以及診斷能力的不斷增強，也推動了市場需求。已開發市場和新興市場醫療保健支出的成長進一步促進了市場發展。

主要促進因素包括慢性病和罕見病患疾病的上升、血漿分餾技術的進步以及對免疫球蛋白的強勁需求。血漿採集網路的擴展和監管核准的推進，使得供給能力不斷提高。然而，對捐捐血漿的依賴以及嚴格的監管要求可能會限制其快速擴張。

隨著研究不斷開發新的治療應用，前景依然強勁。全球血漿捐獻活動的增加和處理技術的進步將有助於維持供應穩定。隨著醫療系統優先考慮特化生物療法，市場預計將穩定成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球血漿蛋白治療市場：依產品分類

• 市場分析、洞察與預測
• 白蛋白
• 免疫球蛋白
• 血漿衍生因子VIII
• 其他

第5章 全球血漿蛋白治療市場：依應用分類

• 市場分析、洞察與預測
• 血友病
• 原發性免疫力缺乏（PIDD）
• 特發性血小板減少紫斑症（ITP）
• 其他

第6章 全球血漿蛋白治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • CSL
  • Grifols SA
  • Takeda
  • Octapharma AG
  • Biotest AG
  • Kedrion SPA
  • China Biologic Products Holdings Inc
  • Sanquin
  • LFB SA
  • ADMA Biologics Inc
  • Bioverativ

The Plasma Protein Therapeutic Market size is expected to reach USD 43.01 Billion in 2034 from USD 23.85 Billion (2025) growing at a CAGR of 6.77% during 2026-2034.

The global plasma protein therapeutic market is expanding due to increasing use of plasma-derived products for treating immune deficiencies, bleeding disorders, and neurological conditions. Rising awareness of rare diseases and expanding diagnostic capabilities are boosting demand. Growing healthcare expenditure in developed and emerging economies further supports market growth.

Major drivers include increasing prevalence of chronic and rare diseases, advancements in plasma fractionation technologies, and strong demand for immunoglobulins. Expanding plasma collection networks and regulatory approvals enhance supply capacity. However, reliance on donor plasma and stringent regulatory requirements may limit rapid expansion.

Future prospects remain strong as research advances new therapeutic applications. Increasing global plasma donation initiatives and technological improvements in processing will support supply stability. The market is expected to grow steadily as healthcare systems prioritize specialized biologic therapies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Albumin
• Immunoglobulin
• Plasma-derived Factor VIII
• Others

By Application

• Hemophilia
• Primary Immunodeficiency Disorder (PIDD)
• Idiopathic Thrombocytopenic Purpura (ITP)
• Others

COMPANIES PROFILED

• CSL, Grifols SA, Takeda, Octapharma AG, Biotest AG, Kedrion SpA, China Biologic Products Holdings Inc, Sanquin, LFB SA, ADMA Biologics Inc, Bioverativ
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PLASMA PROTEIN THERAPEUTIC MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Albumin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunoglobulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Plasma-derived Factor VIII Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PLASMA PROTEIN THERAPEUTIC MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Hemophilia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Primary Immunodeficiency Disorder (PIDD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Idiopathic Thrombocytopenic Purpura (ITP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PLASMA PROTEIN THERAPEUTIC MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PLASMA PROTEIN THERAPEUTIC INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 CSL
  • 8.2.2 Grifols S.A
  • 8.2.3 Takeda
  • 8.2.4 Octapharma AG
  • 8.2.5 Biotest AG
  • 8.2.6 Kedrion S.P.A
  • 8.2.7 China Biologic Products Holdings Inc
  • 8.2.8 Sanquin
  • 8.2.9 LFB S.A
  • 8.2.10 ADMA Biologics Inc
  • 8.2.11 Bioverativ